Gapping up
In reaction to earnings/guidance:
- CLFD +10.8% (also reinstates and increases repurchase program to $22 mln), FFBC +8.9%, TEAM +7.3%, NATI +7%, OSCR +6.9%, BZH +5.1%, V +3.4%, MITK +3.3%, ETD +3.1%, AAPL +2.4%, CP +1.8%, X +0.9% (also authorizes new $500 mln stock repurchase program)
Other news:
- PRVB +13.5% (to resubmit BLA application for delay of clinical type 1 diabetes following FDA meeting)
- WTFC +7.4% (increases dividend)
- FIXX +4% (Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner)
- MATX +2.7% (adds 3 mln shares to existing share repurchase authorization)
- OHI +1.1% (authorizes new $500 mln share repurchase program)
Analyst comments:
- CFR +6% (upgraded to Outperform from Mkt Perform at Raymond James)
- CHPT +2.9% (upgraded to Overweight from Neutral at JP Morgan)
- CMBM +2.7% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- IOVA +1.7% (upgraded to Buy from Hold at Stifel)
- CALX +1.6% (upgraded to Buy from Hold at Craig Hallum)